Drugs / N1087
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07303322 | Jan 2027 → Jul 2028 expected | androgenetic alopecia | Eurofarma Laboratorios S.A. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N1087 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07303322 ↗ |
| Route | Oral | “Administered orally once daily for a total of 24 weeks.” NCT07303322 ↗ |